APIXABAN - search results

accord healthcare s.l.u. - apixaban - venous thromboembolism; stroke; arthroplasty - antithrombotic agents - prevention of venous thromboembolic events (vte) in adult patients who have undergone elective hip or knee replacement surgery.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii).treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults (see section 4.4 for haemodynamically unstable pe patients).prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (nvaf), with one or more risk factors, such as prior stroke or transient ischaemic attack (tia); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (nyha class ≥ ii).treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults (see section 4.4 for haemodynamically unstable pe patients).

United States - English - NLM (National Library of Medicine)

eliquis- apixaban tablet, film coated

cardinal health 107, llc - apixaban (unii: 3z9y7uwc1j) (apixaban - unii:3z9y7uwc1j) - apixaban 2.5 mg - eliquis is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. eliquis is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe), in patients who have undergone hip or knee replacement surgery. eliquis is indicated for the treatment of dvt. eliquis is indicated for the treatment of pe. eliquis is indicated to reduce the risk of recurrent dvt and pe following initial therapy. eliquis is contraindicated in patients with the following conditions: the limited available data on eliquis use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. treatment may increase the risk of bleeding during pregnancy and delivery. in animal reproduction studies, no adverse developmental effects were seen when apixaban was administered to rats (orally), rabbits (intravenously) and mice (orally) during organogenesis at unbound apixaban exposu

United States - English - NLM (National Library of Medicine)

eliquis- apixaban tablet, film coated eliquis 30-day starter pack- apixaban kit

e.r. squibb & sons, l.l.c. - apixaban (unii: 3z9y7uwc1j) (apixaban - unii:3z9y7uwc1j) - apixaban 2.5 mg - eliquis is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. eliquis is indicated for the prophylaxis of deep vein thrombosis (dvt), which may lead to pulmonary embolism (pe), in patients who have undergone hip or knee replacement surgery. eliquis is indicated for the treatment of dvt. eliquis is indicated for the treatment of pe. eliquis is indicated to reduce the risk of recurrent dvt and pe following initial therapy. eliquis is contraindicated in patients with the following conditions: the limited available data on eliquis use in pregnant women are insufficient to inform drug-associated risks of major birth defects, miscarriage, or adverse developmental outcomes. treatment may increase the risk of bleeding during pregnancy and delivery. in animal reproduction studies, no adverse developmental effects were seen when apixaban was administered to rats (orally), rabbits (intravenously) and mice (orally) during organogenesis at unbound apixaban exposu